Evidence map›Paper›PMID 40517319›Full record

ArticleMolecular oncology2025

Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade.

Tullia C Bruno, Anthony R Cillo

Abstract read
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tullia C BrunoUPMC Hillman Cancer Center, University of Pittsburgh, PA, USA.
Anthony R CilloUPMC Hillman Cancer Center, University of Pittsburgh, PA, USA.ORCID 0000-0002-3213-3129

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combination immunotherapies have entered the treatment armamentarium of oncology, but important knowledge gaps remain in our understanding of how these therapeutics work. A recent study by Rolig, Peng, and colleagues has shed new light on how dual blockade of PD1 and LAG3 enhances antitumor immunity. The authors first interrogated LAG3 expression on T cells across murine tumor models, classifying the models as LAG3

Indexed as

Cellular ReprogrammingImmune Checkpoint InhibitorsT-Lymphocytes, CytotoxicT-Lymphocytes, RegulatoryAnimalsHumansImmunotherapyLymphocyte Activation Gene 3 ProteinMiceProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsLymphocyte Activation Gene 3 ProteinProgrammed Cell Death 1 Receptorcancer immunologyimmuno‐oncologyimmunotherapyregulatory T cellsTreg fragilityTreg stability

Identifiers

PMID40517319
PMCPMC12330920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.